SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 52 filers reported holding SAGE THERAPEUTICS INC in Q3 2014. The put-call ratio across all filers is - and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $12,444,000 | -32.0% | 88,700 | -11.3% | 0.76% | -28.0% |
| Q2 2019 | $18,309,000 | -11.5% | 100,000 | -23.1% | 1.05% | -24.7% |
| Q1 2019 | $20,677,000 | -41.3% | 130,000 | -64.6% | 1.40% | -51.1% |
| Q4 2018 | $35,226,000 | +31.3% | 367,732 | +93.5% | 2.86% | +64.0% |
| Q3 2018 | $26,838,000 | -28.4% | 190,000 | -20.7% | 1.74% | -37.2% |
| Q2 2018 | $37,508,000 | -2.8% | 239,619 | 0.0% | 2.78% | -3.5% |
| Q1 2018 | $38,595,000 | +75.5% | 239,619 | -67.2% | 2.88% | -7.8% |
| Q2 2016 | $21,995,000 | -27.4% | 730,000 | -22.8% | 3.12% | -31.7% |
| Q1 2016 | $30,297,000 | +65.0% | 945,000 | +200.0% | 4.56% | +107.7% |
| Q4 2015 | $18,365,000 | +80.8% | 315,000 | +31.2% | 2.20% | +35.5% |
| Q3 2015 | $10,157,000 | +23520.9% | 240,000 | +28135.3% | 1.62% | +23071.4% |
| Q1 2015 | $43,000 | +16.2% | 850 | -15.0% | 0.01% | +16.7% |
| Q4 2014 | $37,000 | -88.3% | 1,000 | -90.0% | 0.01% | -90.8% |
| Q3 2014 | $315,000 | – | 10,000 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 1,966,688 | $120,204,000 | 10.81% |
| Integral Health Asset Management, LLC | 230,000 | $14,058,000 | 4.30% |
| Asymmetry Capital Management, L.P. | 102,462 | $6,262,000 | 4.02% |
| ACUTA CAPITAL PARTNERS, LLC | 225,000 | $13,752,000 | 3.74% |
| DAFNA Capital Management LLC | 158,306 | $9,676,000 | 3.14% |
| Bain Capital Life Sciences Investors, LLC | 499,100 | $30,505,000 | 2.84% |
| Boxer Capital, LLC | 1,094,000 | $66,865,000 | 2.31% |
| Palo Alto Investors LP | 590,200 | $36,073,000 | 1.98% |
| Logos Global Management LP | 250,000 | $15,280,000 | 1.96% |
| Bellevue Group AG | 1,579,504 | $96,539,000 | 1.33% |